Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists. 2009

Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Okubo-3, Tsukuba, Ibaraki 300-2611, Japan.

The synthesis and biological evaluation of new potent opioid receptor-like 1 antagonists are presented. A structure-activity relationship (SAR) study of arylpyrazole lead compound 1 obtained from library screening identified compound 31, (1S,3R)-N-{[1-(3-chloropyridin-2-yl)-5-(5-fluoro-6-methylpyridin-3-yl)-4-methyl-1H-pyrazol-3-yl]methyl}-3-fluorocyclopentanamine, which exhibits high intrinsic potency and selectivity against other opioid receptors and hERG potassium channel.

UI MeSH Term Description Entries
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D003517 Cyclopentanes A group of alicyclic hydrocarbons with the general formula R-C5H9. Cyclopentadiene,Cyclopentadienes,Cyclopentene,Cyclopentenes,Cyclopentane
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072237 ERG1 Potassium Channel One of three members of the ether-a-go-go (EAG) POTASSIUM CHANNELS gene family comprising ether-a-go-go (eag), eag-like (elk) and eag-related (erg) subfamilies. Ether-a-go-go-related gene 1 (ERG1) also known as KCNH2, encodes the pore-forming subunit of a rapidly activating-delayed rectifier potassium channel that plays an essential role in the final repolarization of ventricular action potential. Loss-of-function mutations in human hERG1 is associated with life-threatening ARRHYTHMIA. Ether-A-Go-Go-Related Potassium Channel 1,Kv11.1 Protein-Potassium Channel,Potassium Voltage-Gated Channel, Subfamily H, Member 2,Channel, ERG1 Potassium,Channel, Kv11.1 Protein-Potassium,Ether A Go Go Related Potassium Channel 1,Kv11.1 Protein Potassium Channel,Potassium Channel, ERG1,Protein-Potassium Channel, Kv11.1
D000094942 Nociceptin Receptor A member of the opioid subfamily of the G PROTEIN-COUPLED RECEPTORS. It is the receptor for the endogenous neuropeptide nociceptin. It functions in modulating NOCICEPTION and the perception of pain. KOR-3 Protein,Kappa3-Related Opioid Receptor,MOR-C Protein,Nociceptin Receptors,OFQ Receptor,OFQ Receptors,ORL1 Receptor,ORL1 Receptors,Opiate Receptor-Like 1,Opioid Receptor-Like Protein,Opioid-Receptor-Like 1 Protein,Orphanin FQ Receptor,Orphanin FQ Receptors,Receptor, Nociceptin,Receptor, OFQ,Receptor, Orphanin FQ,Receptors, ORL1,Noci-R,1 Protein, Opioid-Receptor-Like,1, Opiate Receptor-Like,FQ Receptor, Orphanin,FQ Receptors, Orphanin,MOR C Protein,Noci R,Opioid Receptor Like 1 Protein,Protein, KOR-3,Protein, MOR-C,Protein, Opioid Receptor-Like,Protein, Opioid-Receptor-Like 1,Receptor, Kappa3-Related Opioid,Receptor-Like 1, Opiate,Receptor-Like Protein, Opioid,Receptors, Nociceptin,Receptors, Orphanin FQ
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051638 Ether-A-Go-Go Potassium Channels A family of voltage-gated potassium channels that are characterized by long N-terminal and C-terminal intracellular tails. They are named from the Drosophila protein whose mutation causes abnormal leg shaking under ether anesthesia. Their activation kinetics are dependent on extracellular MAGNESIUM and PROTON concentration. ERG Potassium Channels,Eag Potassium Channels,Eag-Related Potassium Channels,Ether-A-Go-Go Related Potassium Channels,Eag Related Potassium Channels,Ether A Go Go Potassium Channels,Ether A Go Go Related Potassium Channels,Potassium Channels, ERG,Potassium Channels, Eag,Potassium Channels, Eag-Related,Potassium Channels, Ether-A-Go-Go
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
June 2008, Bioorganic & medicinal chemistry letters,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
January 2009, Bioorganic & medicinal chemistry,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
August 2013, Bioorganic & medicinal chemistry letters,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
June 2009, Bioorganic & medicinal chemistry letters,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
April 2010, Bioorganic & medicinal chemistry letters,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
April 2009, Bioorganic & medicinal chemistry letters,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
February 1987, Journal of medicinal chemistry,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
June 2009, Bioorganic & medicinal chemistry letters,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
January 2004, Bioorganic & medicinal chemistry letters,
Kensuke Kobayashi, and Minaho Uchiyama, and Hirokatsu Ito, and Hirobumi Takahashi, and Takashi Yoshizumi, and Hiroki Sakoh, and Yasushi Nagatomi, and Masanori Asai, and Hiroshi Miyazoe, and Tomohiro Tsujita, and Mioko Hirayama, and Satoshi Ozaki, and Takeshi Tani, and Yasuyuki Ishii, and Hisashi Ohta, and Osamu Okamoto
August 2010, Journal of medicinal chemistry,
Copied contents to your clipboard!